Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses RNAi Patent Applications from Cold Spring Harbor Laboratory

NEW YORK, Jan. 22 (GenomeWeb News) - Alnylam Pharmaceuticals has licensed RNAi-related patent applications from Cold Spring Harbor Laboratory, the company said today.

 

Alnylam, based in Cambridge, Mass., obtained a non-exclusive license for the therapeutic use of patent applications and related technology that cover gene silencing in mammalian cells by small interfering RNA.

 

CSHL's intellectual property in this area came out of research conducted by Gregory Hannon.

 

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.